Potential health benefits of avenanthramides of oats

Nutrition Reviews

Volumn 67, Issue 12, 2009, Pages 731-735

  Meydani, Mohsen ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Avenanthramides; Inflammation; Oats; Polyphenols; Proliferation

Indexed keywords

AVENANTHRAMIDE DERIVATIVE; POLYPHENOL DERIVATIVE; UNCLASSIFIED DRUG; ANTHRANILIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AVENANTHRAMIDE 2C; AVENANTHRAMIDE-2C;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER PREVENTION; CELL PROTECTION; COLON CANCER; DIETARY FIBER; HUMAN; ISCHEMIC HEART DISEASE; OAT; PHYTOCHEMISTRY; REVIEW; SKIN IRRITATION; VASODILATATION; ANIMAL; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CHEMISTRY; DRUG EFFECT; HEALTH FOOD; PRURITUS;

AVENA;

ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; AVENA SATIVA; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR DISEASES; HEALTH FOOD; HUMANS; PRURITUS; VASODILATION;

EID: 76249129705     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00256.x     Document Type: Review

References (45)

1. Anderson JW. Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. Curr Atheroscler Rep. 2000;2:536-541.
2. Ness AR, Powles JW. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol. 1997;26:1-13.
3. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA. 1995;273:1113-1117.
4. Joshipura KJ, Hu FB, Manson JE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 2001;134:1106-1114.
5. Anderson JW. Whole grains protect against atherosclerotic cardiovascular disease. Proc Nutr Soc. 2003;62:135-142.
6. Slavin J, Jacobs D, Marquart L.Whole-grain consumption and chronic disease: protective mechanisms. Nutr Cancer. 1997;27:14-21.
7. Kelly SA, Summerbell CD, Brynes A, et al. Wholegrain cereals for coronary heart disease. Cochrane Database Syst Rev. 2007;2:CD005051.
8. Truswell AS. Cereal grains and coronary heart disease. Eur J Clin Nutr. 2002;56:1-14.
9. Katz DL, Nawaz H, Boukhalil J, et al. Effects of oat and wheat cereals on endothelial responses. Prev Med. 2001;33:476-484.
10. Saltzman E, Das SK, Lichtenstein AH, et al. An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. J Nutr. 2001;131:1465-1470.
11. Collins FW. Oat phenolics: structure, occurence and function. In: Webster FH, ed. Oats: Chemistry and Technology. St. Paul, MN: American Association of Cereal Chemists; 1986:227-295.
12. Emmons CL, Peterson DM, Paul GL. Antioxidant capacity of oat (Avena sativa L.) extracts. 2. In vitro antioxidant activity and contents of phenolic and tocol antioxidants. J Agric Food Chem. 1999;47:4894-4898.
13. Collins FW. Oat phenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J Agric Food Chem. 1989;37:60-66.
14. Collins FW, Mullin WJ. High-performance liquid chromatographic determination of avenanthramides, Naroylanthranilic acid alkaloids from oats. J Chromatogr. 1988;45:363-370.
15. Matsukawa T, Isobe T, Ishihara A, Iwamura H. Occurrence of avenanthramides and hydroxycinnamoyl- CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase activity in oat seeds. Z Naturforsch C. 2000;55:30-36.
16. Okazaki Y, Isobe T, Iwata Y, et al. Metabolism of avenanthramide phytoalexins in oats. Plant J. 2004;39:560-572.
17. Peterson DM, Hahn MJ, Emmons CL. Oat avenanthramides exhibit antioxidant activities in vitro. Food Chemistry. 2002;79:473-478.
18. Bryngelsson S, Dimberg LH, Kamal-Eldin A. Effects of commercial processing on levels of antioxidants in oats (Avena sativa L.). J Agric Food Chem. 2002;50:1890-1896.
19. Dimberg LH, Theander O, Lingnert H. Avenanthramides-a group of phenolic antioxidants in oats. Cereal Chem. 1992;70:637-641.
20. Bratt K, Sunnerheim K, Bryngelsson S, et al. Avenanthramides in oats (Avena sativa L.) and structure-antioxidant activity relationships. J Agric Food Chem. 2003;51:594-600.
21. Chen C-Y, Milbury PE, Li T, et al. Antioxidant capacity and bioavailibility of oat avenanthramides. FASEB J. 2005;19:A1477.
22. Chen CY, Milbury PE, Kwak HK, et al. Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. J Nutr. 2004;134:1459-1466.
23. Peterson DM, Emmons CL, Hibbs AH. Phenolic antioxidants and antioxidant activity in pearling fractions of oat groats. J Cereal Sci. 2001;33:97-103.
24. Emmons CL, Peterson DM. Antioxidant activity and phenolic content of oat as affected by cultivar and location. Crop Sci. 2001;41:1676-1681.
25. Peterson DM. Oat antioxidants. J Cereal Sci. 2001;33:115-129.
26. Ji LL, Lay D, Chung E, et al. Effect of avenathramides on oxidant generation and antioxidant enzyme activity in exercised rats. Nutr Res. 2003;23:1579-1590.
27. O'Moore KM, Vanlandschoot CM, Dickman JR, et al. Effect of avenanthramides on rat skeletal muscle injury induced by lengthening contraction. Med Sci Sports Exer. 2005;37 (Suppl):S466.
28. Liu L, Zubik L, Collins FW, et al. The antiatherogenic potential of oat phenolic compounds. Atherosclerosis. 2004;175:39-49.
29. Collins T. Biology of disease: endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
30. Collins T, Cybulsky MI. NF-kB: pivotal mediator or innocent bystander in atherosclerosis? J Clin Invest. 2001;107:255-264.
31. Guo W, Wise ML, Collins FW, Meydani M. Avenanthramides, polyphenols from oats, inhibit IL-1beta-induced NF-kappaB activation in endothelial cells. Free Radic Biol Med. 2008;44:415-429.
32. Lv N, Song MY, Lee YR, et al. Dihydroavenanthramide D protects pancreatic beta-cells from cytokine and streptozotocin toxicity. Biochem Biophys Res Commun. 2009;387:97-102.
33. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of Tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107:179-185.
34. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J. 1999;138:968-975.
35. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of Tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 1992;60:85-90.
36. Isaji M,Miyata H, Ajisawa Y. Tranilast: a new application in the cardiovascular field as an antiproliferative drug. Cardiovascular Drug Reviews. 1998;16:288-299.
37. Azuma H, Banno K, Yoshimura T. Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol. 1976;58:483-488.
38. Nie L, Wise ML, Peterson DM, Meydani M. Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis. 2006;186:260-266.
39. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868-874.
40. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
41. Nie L, Wise M, Peterson D, Meydani M. Mechanism by which avenanthramide-c, a polyphenol of oats, blocks cell cycle progression in vascular smooth muscle cells. Free Radic Biol Med. 2006;41:702-708.
42. Guo W, Nie L, Wu D, et al. Avenanthramides inhibit proliferation of human colon cancer cell lines in vitro. Nutr Cancer. 2009;in press.
43. Kurtz ES, Wallo W. Colloidal oatmeal: history, chemistry and clinical properties. J Drugs Dermatol. 2007;6:167-170.
44. Sur R, Nigam A, Grote D, et al. Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity. Arch Dermatol Res. 2008;300:569-574.
45. Heuschkel S, Wohlrab J, Schmaus G, Neubert RH. Modulation of dihydroavenanthramide D release and skin penetration by 1,2-alkanediols. Eur J Pharm Biopharm. 2008;70:239-247.